PubMed Health⌕ Search

PubMed · 10635847

[Echo viruses].

Abstract

The source did not provide an abstract. Follow the original record for more information.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

H Shoji. 1999. [Echo viruses].. https://pubmed.ncbi.nlm.nih.gov/10635847/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Evaluation of the Wampole Laboratories ELISA-based assay for Epstein-Barr virus serology.

BACKGROUND: Epstein-Barr virus (EBV) infection is associated with infectious mononucleosis, Burkitt's lymphoma, and nasopharyngeal carcinoma. Serologic diagnosis of acute EBV infections has been the method of choice, and tests are available as indirect fluorescent antibody (IFA)- and ELISA-based assays. OBJECTIVE: To evaluate the ELISA-based EBV assay from Wampole Laboratories (Cranbury, NJ). METHODS: One hundred fifty-two consecutive samples received for comprehensive EBV serology were analyzed. RESULTS: A comparison of the Wampole Laboratories' ELISA system with the Gull/Meridian Diagnostics (Cincinnati, OH) IFA, and ELISA assays showed 88% concordance for anti-viral capsid antigen (VCA) IgM (n=177); 79% concordance for anti-VCA IgG (n=177); 87% concordance for anti-NA IgG (n=172); and 48% concordance for anti-EA IgG (n=165). Using the results from all four antibody assays to identify patients with acute infection, the Wampole system had a 67% concordance with the Gull/Meridian (n=164). CONCLUSIONS: Differences in the specificity of the anti-EA IgG assays (i.e. reactivity against the D component of early antigen (EA-D) (Wampole) vs. reactivity to EA-D and the R component of early antigen (EA-R) (Gull/Meridian)) may have lead to poor concordance (48%) for this particular assay. Because the Wampole system had a <70% overall concordance with the Gull/Meridian system in diagnosis of acute infection, these data suggest that further studies are needed to determine the true clinical sensitivity and specificity of this system.

Antibodies, Viral↗

Effect of vitamin A supplementation on measles-specific antibody levels in Guinea-Bissau.

We have previously reported that vitamin A supplementation with measles vaccine at age 9 months increases measles-specific antibody concentrations in children at age 18 months compared with placebo. We examined these children when they reached age 6-8 years. Fewer vitamin A-supplemented children had non-protective antibody concentrations (p=0.0095); among children with protective antibody levels, vitamin A-supplemented children tended to have higher geometric mean antibody titres (p=0.09). Thus, simultaneous administration of vitamin A and measles vaccine at age 9 months had a long-term effect on measles-specific antibody levels and may contribute to improved measles control in less-developed countries.

Antibodies, Viral↗

Antibodies to varicella-zoster virus in blood donors with genetic variance in CC chemokine receptor 5.

Carriers of a 32 bp deletion (Delta32) allele of the CC chemokine receptor 5 (CCR5) gene are reported to be more likely to lack antibodies to varicella-zoster virus than CCR5 wild-type individuals. To find out whether CCR5-Delta32 is associated with the seroprevalence of varicella-zoster virus infection, we tested blood donors with different CCR5-Delta32 genotypes for varicella-zoster virus IgG. Antibody to varicella-zoster virus was present in 209 (99.5%) of 210 CCR5-Delta32 carriers and exactly the same proportion of CCR5 wild-type individuals (209 of 210). We have therefore found no evidence that the CCR5-Delta32 allele is associated with decreased seroprevalence of varicella-zoster virus infection.

Antibodies, Viral↗